IL258397A - Anti-age antibodies and methods of use thereof - Google Patents

Anti-age antibodies and methods of use thereof

Info

Publication number
IL258397A
IL258397A IL258397A IL25839718A IL258397A IL 258397 A IL258397 A IL 258397A IL 258397 A IL258397 A IL 258397A IL 25839718 A IL25839718 A IL 25839718A IL 258397 A IL258397 A IL 258397A
Authority
IL
Israel
Prior art keywords
methods
age antibodies
antibodies
age
Prior art date
Application number
IL258397A
Other languages
Hebrew (he)
Original Assignee
Siwa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/974,561 external-priority patent/US10358502B2/en
Application filed by Siwa Corp filed Critical Siwa Corp
Publication of IL258397A publication Critical patent/IL258397A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
IL258397A 2015-10-13 2018-03-27 Anti-age antibodies and methods of use thereof IL258397A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562241007P 2015-10-13 2015-10-13
US14/974,561 US10358502B2 (en) 2014-12-18 2015-12-18 Product and method for treating sarcopenia
PCT/US2016/034880 WO2017065837A1 (en) 2015-10-13 2016-05-27 Anti-age antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
IL258397A true IL258397A (en) 2018-05-31

Family

ID=58518256

Family Applications (1)

Application Number Title Priority Date Filing Date
IL258397A IL258397A (en) 2015-10-13 2018-03-27 Anti-age antibodies and methods of use thereof

Country Status (12)

Country Link
EP (1) EP3362483A1 (en)
JP (1) JP2018535953A (en)
KR (1) KR20180056689A (en)
CN (1) CN108431044A (en)
AU (1) AU2016336959A1 (en)
BR (1) BR112018007422A2 (en)
CA (1) CA3000815C (en)
IL (1) IL258397A (en)
MA (1) MA42979A (en)
MX (1) MX2018004545A (en)
RU (1) RU2766209C2 (en)
WO (1) WO2017065837A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104987416A (en) 2008-05-23 2015-10-21 Siwa有限公司 Methods, compositions and apparatus for facilitating regeneration
US9649376B2 (en) 2010-09-27 2017-05-16 Siwa Corporation Selective removal of age-modified cells for treatment of atherosclerosis
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
RU2721568C2 (en) 2014-09-19 2020-05-20 Сива Корпорейшн Anti-age antibodies for treating inflammation and autoimmune disorders
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US10889634B2 (en) 2015-10-13 2021-01-12 Siwa Corporation Anti-age antibodies and methods of use thereof
AU2017219749B2 (en) * 2016-02-19 2022-01-06 Siwa Corporation Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (AGE)
WO2017181116A1 (en) 2016-04-15 2017-10-19 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
JP2019518763A (en) 2016-06-23 2019-07-04 シワ コーポレーション Vaccines for use in the treatment of various diseases and disorders
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
US10919957B2 (en) 2017-04-13 2021-02-16 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
CA3062082A1 (en) * 2017-05-04 2018-11-08 Siwa Corporation Diagnostic advanced glycation end-product antibodies
JP6994876B2 (en) * 2017-09-05 2022-01-14 株式会社エッグ Measuring instrument
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
WO2019183282A1 (en) * 2018-03-21 2019-09-26 Mayo Foundation For Medical Education And Research Senolytic agents for the treatment of tauopathies
US20220175916A1 (en) * 2018-07-23 2022-06-09 Siwa Corporation Methods and compositions for treating chronic effects of radiation and chemical exposure
JP2021534144A (en) * 2018-08-23 2021-12-09 シワ コーポレーション Anti-carboxymethyl lysine antibody and ultrasound to remove AGE-modified cells
CA3177449A1 (en) * 2020-05-01 2021-11-04 Lewis S. Gruber Methods of treating infections
EP4337332A2 (en) * 2021-07-13 2024-03-20 Mabwell Therapeutics Inc. Anti-c1s antibodies and uses thereof
CN114957470B (en) * 2021-11-12 2023-01-17 深圳市人民医院 Nanobody targeting RAGE and its application
WO2023177390A1 (en) * 2022-03-14 2023-09-21 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody for treating pancreatic cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US4917951A (en) 1987-07-28 1990-04-17 Micro-Pak, Inc. Lipid vesicles formed of surfactants and steroids
US5624804A (en) 1991-12-20 1997-04-29 The Rockefeller University Immunochemical detection of In vivo advanced glycosylation end products
US6387373B1 (en) 1993-01-15 2002-05-14 Novavax, Inc. Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants
US6380165B1 (en) 1997-09-19 2002-04-30 The Picower Institute For Medical Research Immunological advanced glycation endproduct crosslink
KR100850389B1 (en) * 1999-06-25 2008-08-04 제넨테크, 인크. Humanized Anti-ErbB2 Antibodies and Treatment with Anti-ErbB2 Antibodies
JP4012722B2 (en) * 2001-11-22 2007-11-21 株式会社トランスジェニック Antibodies against carboxymethylated peptides
WO2007098186A2 (en) 2006-02-22 2007-08-30 Novavax, Inc. Adjuvant and vaccine compositions
CN104987416A (en) 2008-05-23 2015-10-21 Siwa有限公司 Methods, compositions and apparatus for facilitating regeneration

Also Published As

Publication number Publication date
JP2018535953A (en) 2018-12-06
BR112018007422A2 (en) 2018-10-30
RU2018110885A (en) 2019-11-19
WO2017065837A1 (en) 2017-04-20
MX2018004545A (en) 2018-08-01
AU2016336959A1 (en) 2018-04-12
CA3000815A1 (en) 2017-04-20
CA3000815C (en) 2022-11-01
CN108431044A (en) 2018-08-21
RU2766209C2 (en) 2022-02-09
MA42979A (en) 2021-05-26
EP3362483A1 (en) 2018-08-22
KR20180056689A (en) 2018-05-29
RU2018110885A3 (en) 2020-01-30

Similar Documents

Publication Publication Date Title
IL304117A (en) Anti-pvrig antibodies and methods of use
IL279606A (en) Anti-trem2 antibodies and methods of use thereof
IL258397A (en) Anti-age antibodies and methods of use thereof
IL259495A (en) Antibodies and methods of use thereof
IL257636A (en) Anti-tigit antibodies and methods of use
IL254887A0 (en) Anti-sortilin antibodies and methods of use thereof
SG11201803567XA (en) Anti-siglec-9 antibodies and methods of use thereof
SG10201912150TA (en) Anti-trem2 antibodies and methods of use thereof
IL259681A (en) Novel anti-claudin antibodies and methods of use
ZA202001985B (en) Anti-htra1 antibodies and methods of use thereof
HK1259818A1 (en) Anti-age antibodies and methods of use thereof